



Comment on “New therapeutic agents in diabetic nephropathy”

Alain Gay and Peter Kolkhof

Bayer AG, Berlin, Germany

We have read with great interest the article “New therapeutic agents in diabetic nephropathy” Korean J Intern Med 2017;32:11-25 by Yaeni Kim and Cheol Whee Park [1]. The authors stated that ‘the Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY) trial using mineralocorticoid receptor blockers (MT-3995, BAY 94-3995, and BAY 94-8862) has shown limited efficacy in the early stages of diabetic nephropathy and concerns regarding the development of hyperkalemia need to be addressed.

This statement is not correct because: (1) the PRIORITY study is still ongoing, the results have not been reported yet [2]; (2) secondly the drug being tested is this research is spironolactone and not MT-3995, BAY 94-3995, and BAY 94-8862; and (3) BAY 94-3995 does not exist.

If the authors would rather refer to BAY 94-8862 then we would like to underline the following: BAY 94-8862 has now an INN (international nonproprietary name) which is finerenone. Finerenone has shown in a phase IIb study in patients with diabetic kidney disease (DKD) a significant and dose-dependent reduction of urine albumin-to-creatinine ratio after 90 days. Hyperkalemia leading to discontinuation was not observed in the placebo and finerenone 10

mg groups; the incidence was 3.2% in the 15 mg group and \leq 2.2% in all other finerenone groups. Therefore, the risk of hyperkalemia was low in patients with DKD who received finerenone for 90 days in addition to standard of care [3].

We hope that the authors will correct their publication accordingly.

Conflict of interest

Alain Gay and Peter Kolkhof work for Bayer AG; however, no potential conflict of interest relevant to this article was reported.

REFERENCES

1. Kim Y, Park CW. New therapeutic agents in diabetic nephropathy. Korean J Intern Med 2017;32:11-25.
2. Lindhardt M, Persson F, Currie G, et al. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. *BMJ Open* 2016;6:e010310.
3. Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. *JAMA* 2015;314:884-894.

Received: March 15, 2017
Accepted: April 12, 2017

Correspondence to
Alain Gay, M.D.

Bayer AG, Mullerstrasse, 178,
Berlin 13342, Germany
Tel: +49-3046-8192003
Fax: +49-3046-8992003
E-mail: alain.gay@bayer.com